Brammer BIO Plans New Viral Manufacturing Facility
Brammer Bio, a cell and gene therapy contract development and manufacturing organization (CDMO), iplans to build-out a 50,000-square-foot facility dedicated to late-phase development, including Phase III and commercial production of viral vector-based and cell-based advanced therapies. The facility, which will be in Lexington, Massachusetts, will be qualified and operational by the second quarter of 2017.
Brammer Bio LLC was founded early in 2015 to create a cell and gene therapy CDMO. The company operates process development and Phase I/II clinical manufacturing in Alachua, Florida and is now building out the Lexington facility to meet Phase III development and manufacturing needs.
Source: Brammer Bio